Table 2. Association between tissue factor (TF) protein expression and clinical characteristics.
| Characteristic | All (n=50) (%) | High TF (n=13) (%) | Normal TF (n=37) (%) | P value (χ2-test) |
|---|---|---|---|---|
| Sex, n (%) | 0.877 | |||
| Male | 24 (48.0) | 6 (46.2) | 18 (48.6) | |
| Female | 26 (52.0) | 7 (53.8) | 19 (51.4) | |
| Age (years), n (%) | 0.640 | |||
| ≤60 | 28 (56.0) | 8 (61.5) | 20 (54.1) | |
| >60 | 22 (44.0) | 5 (38.5) | 17 (45.9) | |
| ECOG PS, n (%) | 0.527 | |||
| 0–1 | 43 (86.0) | 10 (76.9) | 33 (89.2) | |
| 2–4 | 7 (14.0) | 3 (23.1) | 4 (10.8) | |
| Smoking history, n (%) | 0.778 | |||
| Never | 35 (70.0) | 10 (76.9) | 25 (67.6) | |
| Past/current smoker | 15 (30.0) | 3 (23.1) | 12 (32.4) | |
| ALK status, n (%) | 0.015 | |||
| Positive | 24 (48.0) | 10 (76.9) | 14 (37.8) | |
| Negative | 26 (52.0) | 3 (23.1) | 23 (62.2) | |
| VTE, n (%) | 0.013 | |||
| Yes | 7 (14.0) | 5 (38.5) | 2 (5.4) | |
| No | 43 (86.0) | 8 (61.5) | 35 (94.6) |
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; VTE, venous thromboembolism; ECOG PS, Eastern Cooperative Oncology Group performance status.